Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) from a sell rating to a strong sell rating in a research note released on Saturday morning.

Separately, Weiss Ratings assumed coverage on Lakewood-Amedex Biotherapeutics in a research report on Monday, July 20th. They issued a “sell (e-)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of NASDAQ LABT opened at $2.30 on Friday. The firm has a market cap of $5.45 million and a P/E ratio of -0.48. The business’s 50 day moving average price is $2.54. Lakewood-Amedex Biotherapeutics has a 1 year low of $1.66 and a 1 year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last released its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. As a group, equities research analysts forecast that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current fiscal year.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.